98 related articles for article (PubMed ID: 12772191)
1. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Fortier AH; Holaday JW; Liang H; Dey C; Grella DK; Holland-Linn J; Vu H; Plum SM; Nelson BJ
Prostate; 2003 Aug; 56(3):212-9. PubMed ID: 12772191
[TBL] [Abstract][Full Text] [Related]
2. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
[TBL] [Abstract][Full Text] [Related]
3. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
5. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic activity of PSA-derived peptides.
Chadha KC; Nair B; Godoy A; Rajnarayanan R; Nabi E; Zhou R; Patel NR; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2015 Sep; 75(12):1285-99. PubMed ID: 25963523
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic action of plasma hyaluronan binding protein in human umbilical vein endothelial cells.
Jeon JW; Song HS; Moon EJ; Park SY; Son MJ; Jung SY; Kim JT; Nam DH; Choi-Miura NH; Kim KW; Kim YJ
Int J Oncol; 2006 Jul; 29(1):209-15. PubMed ID: 16773202
[TBL] [Abstract][Full Text] [Related]
9. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
10. [Procaryotic expression, purification and identification of recombinant human prostate-specific antigen].
Wang ZJ; Zhang W; Wu HF; Sui YG
Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1080-3. PubMed ID: 18284054
[TBL] [Abstract][Full Text] [Related]
11. Expression and purification of recombinant active prostate-specific antigen from Escherichia coli.
Jeong S; Lee SW
J Microbiol Biotechnol; 2007 May; 17(5):840-6. PubMed ID: 18051307
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Gallardo-Williams MT; Maronpot RR; Wine RN; Brunssen SH; Chapin RE
Prostate; 2003 Jan; 54(1):44-9. PubMed ID: 12481254
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
Oliver VK; Patton AM; Desai S; Lorang D; Libutti SK; Kohn EC
J Cell Physiol; 2003 Oct; 197(1):139-48. PubMed ID: 12942550
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Zachary I
IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
16. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
Benndorf R; Böger RH; Ergün S; Steenpass A; Wieland T
Circ Res; 2003 Sep; 93(5):438-47. PubMed ID: 12881481
[TBL] [Abstract][Full Text] [Related]
18. Production of an anti-prostate-specific antigen single-chain antibody fragment from Pichia pastoris.
Wang Y; Wang K; Jette DC; Wishart DS
Protein Expr Purif; 2001 Dec; 23(3):419-25. PubMed ID: 11722178
[TBL] [Abstract][Full Text] [Related]
19. Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
Lee SB; Oh HK; Kim HK; Joe YA
Protein Expr Purif; 2006 Nov; 50(1):1-8. PubMed ID: 16854593
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
Aalamian M; Tourkova IL; Chatta GS; Lilja H; Huland E; Huland H; Shurin GV; Shurin MR
J Urol; 2003 Nov; 170(5):2026-30. PubMed ID: 14532846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
